ArticleBMC ophthalmology2025
12-month clinical outcomes of the Evolux™ extended monofocal intraocular lens following cataract surgery.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Visual and Patient-Reported Outcomes After Bilateral Implantation of Two Enhanced Monofocal IOLs.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the visual performance of a non-diffractive extended monofocal intraocular lens (Evolux™; SIFI, Catania, Italy) 12 months following cataract surgery.
methodsThis retrospective, non-randomized, single-arm study included 116 eyes from 82 patients who underwent cataract surgery with Evolux™ IOL implantation. Patients underwent preoperative and postoperative assessments including uncorrected and best-corrected distance (UDVA, CDVA) and near visual acuity (UNVA, CNVA), as well as refractive accuracy and defocus curve evaluation. Postoperative measurements were recorded at 1, 3, 6, and 12 months.
resultsAt 12 months postoperatively, UDVA improved from 0.89 ± 0.54 logMAR to 0.10 ± 0.14 logMAR (p < 0.001), and CDVA improved from 0.41 ± 0.40 logMAR to 0.04 ± 0.08 logMAR (p < 0.001). 62% of eyes achieved a UDVA of 20/20 or better, while 96% reached at least 20/40. Refractive accuracy was high, with 76% of eyes achieving a postoperative spherical equivalent within ± 0.50 D and 95% within ± 1.00 D, indicating strong predictability. The defocus curve confirmed functional vision of 0.2 logMAR or better across a continuous defocus range of 2.00 D, supporting effective intermediate and near vision.
conclusionEvolux™ demonstrated good distance vision and enhanced intermediate vision without the visual disturbances commonly associated with multifocal or diffractive extended depth-of-focus IOLs. These findings suggest that Evolux™ is an effective solution for patients seeking greater spectacle independence and improved functional vision following cataract surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.